Hospital
Bridgeport Hospital
Bridgeport Hospital was paid $287.34M by Medicaid between Jan 2018 and Dec 2024, across 702 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoBRIDGEPORT HOSPITAL
BRIDGEPORT, CT 06610
BRIDGEPORT, CT 06610
33aNPI1992910152assigned 05/11/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$287.34M
24GClaims7,011,413
24DCodes billed702
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Connecticut
Rank by total paid#2 of 18
Median peer was paid$15.60M
This provider vs. median18×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WRINN, JACQUELINE controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 845,107 | $39.43M | |
| 2019 | 856,388 | $40.47M | |
| 2020 | 839,040 | $33.41M | |
| 2021 | 1,173,348 | $46.27M | |
| 2022 | 1,082,070 | $44.00M | |
| 2023 | 1,161,694 | $42.84M | |
| 2024incomplete | 1,053,766 | $40.92M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 211,494 | 190,221 | $53.55M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 82,315 | 73,073 | $45.26M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 223,006 | 205,412 | $31.53M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 8.1% | 217,964 | 159,578 | $23.15M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.6% | 163,580 | 44,723 | $10.35M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.6% | 52,056 | 44,049 | $7.44M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.6% | 108,493 | 92,678 | $7.35M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.0% | 7,982 | 7,120 | $5.71M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 48,728 | 42,941 | $4.60M |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 61,080 | 55,074 | $3.49M |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 1.1% | 35,710 | 30,977 | $3.29M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 14,930 | 13,922 | $3.11M |
690 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 18,754 | $3.05M |
| 59025 | Fetal non-stress test | 1.0% | 18,030 | $2.94M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 3,551 | $2.85M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 24,356 | $2.70M |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 22,288 | $2.47M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 25,560 | $2.37M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 4,917 | $2.16M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13,620 | $1.97M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 3,312 | $1.96M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 17,917 | $1.94M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 36,480 | $1.88M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 85,797 | $1.83M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 29,428 | $1.54M |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 2,466 | $1.41M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 6,240 | $1.34M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,522 | $1.33M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 19,974 | $1.23M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,943 | $1.22M |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 5,751 | $1.18M |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 29,826 | $1.16M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 9,693 | $1.16M |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 9,874 | $1.13M |
| 76830 | Ultrasound, transvaginal | <1% | 11,136 | $1.11M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 21,105 | $1.10M |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 1,606 | $1.07M |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 978 | $952K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 92,592 | $946K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 7,461 | $906K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 6,266 | $893K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 10,293 | $884K |
| 76801 | <1% | 8,113 | $841K | |
| 76641 | <1% | 8,194 | $758K | |
| 47562 | <1% | 178 | $757K | |
| 29581 | <1% | 7,964 | $723K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 31,547 | $716K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,430 | $688K |
| 97161 | <1% | 11,191 | $685K | |
| 97162 | <1% | 12,752 | $668K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 7,314 | $657K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 3,025 | $648K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 1,008 | $640K |
| 58558 | <1% | 317 | $633K | |
| 76770 | <1% | 7,038 | $605K | |
| 15275 | <1% | 637 | $594K | |
| 93976 | <1% | 6,132 | $556K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 16,610 | $507K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,210 | $504K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,084 | $502K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 1,053 | $501K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,002 | $491K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 11,386 | $486K |
| 76857 | <1% | 5,260 | $482K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,399 | $451K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 4,609 | $448K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 1,700 | $446K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 1,885 | $442K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,978 | $434K |
| 94060 | <1% | 2,107 | $434K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,566 | $413K |
| 82947 | <1% | 148,141 | $384K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 2,010 | $382K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 486 | $376K |
| 93971 | <1% | 5,296 | $364K | |
| 77066 | Tomosynthesis, mammo | <1% | 3,008 | $357K |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 5,810 | $357K |
| 70498 | <1% | 2,148 | $356K | |
| 58661 | <1% | 84 | $349K | |
| 76536 | <1% | 4,385 | $344K | |
| 86900 | <1% | 19,680 | $341K | |
| 71250 | <1% | 5,388 | $333K | |
| 77065 | Tomosynthesis, mammo | <1% | 2,862 | $325K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,794 | $316K |
| 93351 | <1% | 857 | $316K | |
| 10060 | <1% | 2,019 | $310K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,227 | $309K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,162 | $300K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 31,581 | $298K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 31,369 | $297K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 2,776 | $289K |
| 76642 | <1% | 4,745 | $284K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 43,058 | $284K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,932 | $283K |
| 97035 | <1% | 3,716 | $281K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 7,001 | $280K |
| 72141 | <1% | 1,220 | $280K | |
| 93970 | <1% | 2,157 | $268K | |
| 74183 | <1% | 1,375 | $267K | |
| 72100 | <1% | 7,474 | $262K | |
| 77336 | <1% | 3,220 | $261K | |
| 20610 | <1% | 1,064 | $259K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 50,457 | $253K |
| 93798 | <1% | 3,940 | $241K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,275 | $238K |
| 93017 | <1% | 4,019 | $233K | |
| 93308 | <1% | 2,019 | $228K | |
| 97018 | <1% | 3,283 | $222K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13,927 | $222K |
| 93458 | <1% | 186 | $218K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 15,229 | $217K |
| 77334 | <1% | 619 | $216K | |
| 77080 | <1% | 2,199 | $213K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 18,620 | $209K |
| 70491 | <1% | 1,334 | $206K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 185,705 | $204K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 76,935 | $194K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 5,289 | $188K |
| 95806 | <1% | 1,541 | $183K | |
| 36561 | <1% | 96 | $183K | |
| 73560 | <1% | 11,953 | $173K | |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | <1% | 280 | $169K |
| 86780 | <1% | 14,172 | $155K | |
| 83718 | <1% | 23,798 | $150K | |
| 97165 | <1% | 2,188 | $139K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 2,675 | $137K |
| 90677 | <1% | 695 | $134K | |
| 36430 | <1% | 1,048 | $132K | |
| 73630 | <1% | 10,771 | $129K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 18,202 | $129K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,730 | $127K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 10,504 | $124K |
| 73221 | <1% | 642 | $123K | |
| 82247 | <1% | 115,718 | $123K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 34,201 | $121K |
| 36415 | Collection of venous blood by venipuncture | <1% | 128,909 | $119K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 6,849 | $116K |
| 97113 | <1% | 1,895 | $115K | |
| 93880 | <1% | 1,215 | $111K | |
| 72110 | <1% | 1,967 | $111K | |
| 77386 | <1% | 268 | $110K | |
| 19083 | <1% | 108 | $108K | |
| 77300 | <1% | 525 | $107K | |
| 73030 | <1% | 9,007 | $107K | |
| 97166 | <1% | 1,424 | $101K | |
| 82040 | <1% | 116,838 | $100K | |
| 70486 | <1% | 3,337 | $99K | |
| 93225 | <1% | 1,740 | $97K | |
| 72197 | <1% | 316 | $95K | |
| 86480 | <1% | 5,032 | $91K | |
| 74018 | <1% | 2,720 | $88K | |
| 76882 | <1% | 1,823 | $84K | |
| 58300 | <1% | 533 | $84K | |
| 97116 | <1% | 5,702 | $83K | |
| 58571 | <1% | 13 | $80K | |
| C9600 | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | <1% | 18 | $79K |
| 77412 | <1% | 699 | $78K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 19,862 | $78K |
| 72070 | <1% | 2,097 | $77K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 440 | $76K |
| 71271 | <1% | 761 | $74K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $74K |
| 77072 | <1% | 723 | $74K | |
| 82607 | <1% | 10,270 | $73K | |
| 86803 | <1% | 15,473 | $72K | |
| 83013 | <1% | 1,786 | $70K | |
| 10061 | <1% | 260 | $70K | |
| 88342 | <1% | 3,067 | $69K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 266 | $68K |
| 82728 | <1% | 11,390 | $66K | |
| 72040 | <1% | 2,687 | $66K | |
| 92523 | <1% | 275 | $66K | |
| 90686 | <1% | 5,158 | $66K | |
| 96415 | <1% | 1,041 | $65K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,307 | $65K |
| 82310 | <1% | 148,871 | $64K | |
| 72050 | <1% | 1,449 | $64K | |
| 73610 | <1% | 8,256 | $63K | |
| 58301 | <1% | 329 | $63K | |
| 70310 | <1% | 881 | $63K | |
| 70496 | <1% | 2,308 | $62K | |
| 73502 | <1% | 4,526 | $61K | |
| 73130 | <1% | 6,729 | $60K | |
| 76870 | <1% | 2,211 | $54K | |
| G0378 | Hospital observation service, per hour | <1% | 75,495 | $52K |
| 87631 | <1% | 10,446 | $52K | |
| 72081 | <1% | 698 | $51K | |
| 83970 | <1% | 3,058 | $50K | |
| 90732 | <1% | 673 | $49K | |
| 94726 | <1% | 1,725 | $49K | |
| 73120 | <1% | 1,051 | $49K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 506 | $48K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 30 | $46K |
| 76825 | <1% | 102 | $45K | |
| 97163 | <1% | 917 | $44K | |
| 81513 | <1% | 2,867 | $43K | |
| 84439 | <1% | 10,832 | $42K | |
| 74178 | <1% | 241 | $42K | |
| 87506 | <1% | 1,121 | $42K | |
| 83550 | <1% | 10,529 | $40K | |
| 73110 | <1% | 5,104 | $39K | |
| 97167 | <1% | 592 | $37K | |
| 95816 | <1% | 248 | $36K | |
| 77062 | <1% | 2,703 | $36K | |
| 73522 | <1% | 852 | $35K | |
| 70220 | <1% | 674 | $35K | |
| 90746 | <1% | 580 | $34K | |
| 95812 | <1% | 171 | $34K | |
| 73700 | <1% | 479 | $34K | |
| 87536 | <1% | 1,420 | $33K | |
| 83540 | <1% | 11,211 | $32K | |
| 58100 | <1% | 226 | $31K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,718 | $31K |
| 87340 | <1% | 11,824 | $30K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 162 | $30K |
| 29515 | <1% | 229 | $30K | |
| 76813 | <1% | 5,735 | $29K | |
| 52356 | <1% | 13 | $29K | |
| 0240U | <1% | 266 | $29K | |
| 90836 | <1% | 407 | $29K | |
| 74019 | <1% | 3,789 | $29K | |
| 82746 | <1% | 3,603 | $28K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 43,990 | $28K |
| 73564 | <1% | 1,367 | $27K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 261 | $27K |
| 84403 | <1% | 1,728 | $25K | |
| 77061 | <1% | 2,018 | $25K | |
| 84702 | <1% | 14,636 | $24K | |
| 82570 | <1% | 13,958 | $24K | |
| 73140 | <1% | 3,260 | $24K | |
| 73590 | <1% | 3,436 | $24K | |
| 87481 | <1% | 3,056 | $23K | |
| 95811 | <1% | 29 | $23K | |
| 93975 | <1% | 137 | $22K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 475 | $22K |
| 52332 | <1% | 14 | $21K | |
| 72170 | <1% | 3,102 | $21K | |
| 92526 | <1% | 334 | $21K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 12,224 | $21K |
| 82374 | <1% | 148,339 | $21K | |
| 86235 | <1% | 721 | $21K | |
| 73562 | <1% | 618 | $20K | |
| 86003 | <1% | 348 | $20K | |
| 82043 | <1% | 8,543 | $20K | |
| 82465 | <1% | 23,932 | $20K | |
| 80061 | Lipid panel | <1% | 10,409 | $19K |
| 76818 | <1% | 197 | $19K | |
| 83735 | <1% | 55,045 | $19K | |
| 85027 | <1% | 18,988 | $19K | |
| 72131 | <1% | 359 | $18K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 86 | $18K |
| 73090 | <1% | 2,885 | $18K | |
| 72158 | <1% | 70 | $18K | |
| 87070 | <1% | 12,694 | $18K | |
| 70360 | <1% | 356 | $18K | |
| 85610 | <1% | 29,777 | $17K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 81 | $17K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 387 | $17K |
| 80053 | Comprehensive metabolic panel | <1% | 40,056 | $17K |
| 74174 | <1% | 104 | $16K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,303 | $16K |
| 86140 | <1% | 9,758 | $16K | |
| 73070 | <1% | 928 | $16K | |
| 84146 | <1% | 1,920 | $16K | |
| 86870 | <1% | 88 | $16K | |
| 29705 | <1% | 68 | $16K | |
| 73080 | <1% | 2,895 | $16K | |
| 73552 | <1% | 1,928 | $15K | |
| 87077 | <1% | 12,804 | $15K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,549 | $15K |
| 74220 | <1% | 97 | $14K | |
| 86038 | <1% | 2,934 | $14K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 321 | $14K |
| 84480 | <1% | 1,841 | $14K | |
| 73620 | <1% | 652 | $14K | |
| 86706 | <1% | 3,811 | $14K | |
| 87653 | <1% | 2,491 | $14K | |
| 81001 | <1% | 48,114 | $13K | |
| 90662 | <1% | 1,188 | $13K | |
| 83880 | <1% | 9,051 | $13K | |
| 43235 | <1% | 29 | $13K | |
| 86618 | <1% | 2,435 | $13K | |
| 86360 | <1% | 1,028 | $13K | |
| 84153 | <1% | 1,450 | $13K | |
| 84478 | <1% | 24,056 | $12K | |
| 80197 | <1% | 1,490 | $12K | |
| 92610 | <1% | 114 | $12K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,411 | $12K |
| 87186 | <1% | 11,741 | $12K | |
| 82784 | <1% | 1,711 | $12K | |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 495 | $12K |
| 83001 | <1% | 1,221 | $12K | |
| 70544 | <1% | 54 | $11K | |
| 76999 | <1% | 352 | $11K | |
| 71101 | <1% | 1,544 | $11K | |
| 90651 | <1% | 39 | $11K | |
| 86160 | <1% | 917 | $11K | |
| 87522 | Neg quan hep c or qual rna | <1% | 715 | $11K |
| 57454 | <1% | 47 | $10K | |
| 83002 | <1% | 1,100 | $10K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 27 | $10K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 19,589 | $10K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 9,885 | $10K |
| 82950 | <1% | 2,520 | $10K | |
| 83655 | <1% | 981 | $10K | |
| 82670 | <1% | 694 | $10K | |
| 84270 | <1% | 808 | $10K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,165 | $10K |
| 86225 | <1% | 1,662 | $10K | |
| 12001 | <1% | 2,647 | $9K | |
| 84445 | <1% | 294 | $9K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 8,287 | $9K |
| 73060 | <1% | 1,780 | $9K | |
| 0124A | <1% | 388 | $9K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 60 | $9K |
| 82105 | <1% | 1,695 | $9K | |
| 86705 | <1% | 1,689 | $9K | |
| 81003 | <1% | 28,140 | $9K | |
| 85055 | <1% | 2,351 | $8K | |
| 75574 | <1% | 104 | $8K | |
| 83014 | <1% | 1,758 | $8K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 7,902 | $8K |
| 86376 | <1% | 1,186 | $8K | |
| 86704 | <1% | 2,482 | $8K | |
| 74420 | <1% | 640 | $8K | |
| 86762 | <1% | 3,429 | $7K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 17,420 | $7K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,124 | $7K |
| 87205 | <1% | 18,663 | $7K | |
| 86787 | <1% | 3,290 | $7K | |
| 85730 | <1% | 6,616 | $7K | |
| 11721 | <1% | 561 | $7K | |
| 11043 | <1% | 34 | $7K | |
| 72156 | <1% | 12 | $7K | |
| 83921 | <1% | 1,554 | $7K | |
| 73100 | <1% | 333 | $7K | |
| 73600 | <1% | 320 | $6K | |
| 96367 | <1% | 156 | $6K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 35 | $6K |
| 82088 | <1% | 377 | $6K | |
| 91322 | <1% | 255 | $6K | |
| 77301 | <1% | 12 | $6K | |
| 72146 | <1% | 54 | $6K | |
| 86200 | <1% | 1,334 | $6K | |
| 85652 | <1% | 5,690 | $6K | |
| 72082 | <1% | 59 | $6K | |
| 73660 | <1% | 773 | $6K | |
| 82533 | <1% | 750 | $6K | |
| 12011 | <1% | 2,162 | $6K | |
| 0054A | <1% | 306 | $6K | |
| 81025 | <1% | 53,485 | $6K | |
| 88304 | <1% | 3,222 | $6K | |
| 88307 | <1% | 1,886 | $5K | |
| 94010 | <1% | 139 | $5K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 71 | $5K |
| 83690 | <1% | 32,514 | $5K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 123 | $5K |
| 83721 | <1% | 1,400 | $5K | |
| 85007 | <1% | 10,827 | $5K | |
| 77280 | <1% | 46 | $5K | |
| 97597 | <1% | 44 | $5K | |
| 74170 | <1% | 34 | $5K | |
| 86709 | <1% | 961 | $5K | |
| 86431 | <1% | 2,117 | $5K | |
| 86039 | <1% | 1,002 | $4K | |
| 80164 | <1% | 1,730 | $4K | |
| 82627 | <1% | 382 | $4K | |
| 84156 | <1% | 5,235 | $4K | |
| 87075 | <1% | 3,298 | $4K | |
| 93246 | <1% | 146 | $4K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 63 | $4K |
| 83021 | <1% | 2,218 | $4K | |
| 86364 | <1% | 654 | $4K | |
| 90480 | <1% | 243 | $4K | |
| 83516 | <1% | 362 | $4K | |
| 84425 | <1% | 311 | $4K | |
| 86359 | <1% | 1,026 | $4K | |
| 86800 | <1% | 476 | $4K | |
| 84402 | <1% | 303 | $4K | |
| 82951 | <1% | 357 | $4K | |
| 86850 | <1% | 17,747 | $4K | |
| 86923 | <1% | 696 | $4K | |
| 85651 | <1% | 3,555 | $4K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 983 | $4K |
| 84450 | <1% | 115,473 | $3K | |
| 82248 | <1% | 10,692 | $3K | |
| J7300 | Intrauterine copper contraceptive (paragard) | <1% | 17 | $3K |
| 90670 | <1% | 40 | $3K | |
| 95886 | <1% | 224 | $3K | |
| 84244 | <1% | 354 | $3K | |
| 83525 | <1% | 391 | $3K | |
| 88184 | <1% | 70 | $3K | |
| 86765 | <1% | 393 | $3K | |
| 88112 | <1% | 111 | $3K | |
| 87808 | <1% | 15,776 | $3K | |
| 29065 | <1% | 12 | $3K | |
| 29125 | <1% | 954 | $3K | |
| 17250 | <1% | 280 | $3K | |
| 80177 | <1% | 1,232 | $3K | |
| 87088 | <1% | 3,773 | $3K | |
| 0001A | <1% | 78 | $3K | |
| 84165 | <1% | 599 | $3K | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 670 | $2K |
| 85046 | <1% | 1,955 | $2K | |
| 86696 | <1% | 227 | $2K | |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | <1% | 37 | $2K |
| 73000 | <1% | 154 | $2K | |
| 76820 | <1% | 3,549 | $2K | |
| 93271 | <1% | 26 | $2K | |
| 85379 | <1% | 6,547 | $2K | |
| 87081 | <1% | 2,575 | $2K | |
| 86735 | <1% | 296 | $2K | |
| 87632 | <1% | 614 | $2K | |
| 0004A | <1% | 124 | $2K | |
| 88360 | <1% | 341 | $2K | |
| 0031A | <1% | 70 | $2K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 24 | $2K |
| 86769 | <1% | 56 | $2K | |
| 82024 | <1% | 91 | $2K | |
| 86695 | <1% | 227 | $2K | |
| J3490 | Unclassified drugs | <1% | 389,679 | $2K |
| 77338 | <1% | 12 | $2K | |
| 82785 | <1% | 249 | $2K | |
| 93242 | <1% | 95 | $2K | |
| 82140 | <1% | 705 | $2K | |
| 88344 | <1% | 61 | $2K | |
| 83993 | <1% | 136 | $2K | |
| 87449 | <1% | 921 | $2K | |
| 77332 | <1% | 31 | $1K | |
| 82550 | <1% | 5,042 | $1K | |
| 86901 | <1% | 19,619 | $1K | |
| 91200 | <1% | 13 | $1K | |
| 86147 | <1% | 43 | $1K | |
| 0002A | <1% | 34 | $1K | |
| 87040 | <1% | 7,372 | $1K | |
| 83519 | <1% | 179 | $1K | |
| 84484 | <1% | 44,252 | $1K | |
| 84703 | <1% | 346 | $1K | |
| 12002 | <1% | 1,131 | $1K | |
| 97760 | <1% | 34 | $1K | |
| 86256 | <1% | 211 | $1K | |
| 31500 | <1% | 17 | $1K | |
| 70480 | <1% | 14 | $1K | |
| 82962 | <1% | 38,906 | $1K | |
| 81596 | <1% | 29 | $1K | |
| 84520 | <1% | 150,956 | $1K | |
| 84145 | <1% | 3,685 | $1K | |
| 87324 | <1% | 488 | $1K | |
| 83520 | <1% | 131 | $1K | |
| 83521 | <1% | 75 | $951.72 | |
| 84460 | <1% | 116,747 | $918.56 | |
| 84681 | <1% | 98 | $895.24 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,090 | $859.71 |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 13 | $835.55 |
| 82803 | <1% | 3,110 | $823.26 | |
| 94618 | <1% | 98 | $793.44 | |
| 82565 | <1% | 151,021 | $793.35 | |
| 72080 | <1% | 13 | $769.44 | |
| 81002 | <1% | 30,833 | $731.27 | |
| 86255 | <1% | 122 | $690.60 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 178 | $688.99 |
| 90715 | <1% | 5,753 | $681.43 | |
| 87529 | <1% | 549 | $677.80 | |
| 82652 | <1% | 29 | $661.86 | |
| 86334 | <1% | 59 | $661.54 | |
| 11056 | <1% | 13 | $614.64 | |
| 82435 | <1% | 148,569 | $607.38 | |
| 16020 | <1% | 40 | $601.23 | |
| 84550 | <1% | 3,746 | $585.70 | |
| 71100 | <1% | 55 | $585.16 | |
| 0051A | <1% | 19 | $560.00 | |
| 87102 | <1% | 139 | $553.38 | |
| 88302 | <1% | 465 | $549.53 | |
| 99442 | <1% | 20 | $540.96 | |
| 82952 | <1% | 197 | $538.56 | |
| 72202 | <1% | 13 | $501.72 | |
| 83615 | <1% | 2,818 | $483.81 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 39,879 | $479.59 |
| 87468 | <1% | 90 | $474.30 | |
| 83037 | <1% | 3,862 | $462.64 | |
| 87484 | <1% | 90 | $454.97 | |
| 86015 | <1% | 88 | $451.82 | |
| 83605 | <1% | 6,952 | $444.04 | |
| 96376 | <1% | 11,057 | $444.00 | |
| 87493 | <1% | 140 | $435.63 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 12 | $418.69 |
| 84100 | <1% | 9,071 | $414.47 | |
| 84134 | <1% | 77 | $389.76 | |
| 80178 | <1% | 274 | $356.67 | |
| 83835 | <1% | 25 | $355.96 | |
| 84630 | <1% | 54 | $326.10 | |
| 84075 | <1% | 115,008 | $325.64 | |
| 0053A | <1% | 16 | $320.00 | |
| 86258 | <1% | 30 | $319.58 | |
| 86592 | <1% | 99 | $317.46 | |
| 84132 | <1% | 147,258 | $304.80 | |
| 88300 | <1% | 647 | $293.53 | |
| 82075 | <1% | 3,291 | $276.24 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 8,743 | $265.46 |
| 86308 | <1% | 765 | $256.88 | |
| 82010 | <1% | 1,531 | $244.77 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,001 | $236.87 |
| 86708 | <1% | 66 | $224.77 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 781 | $205.90 |
| 86381 | <1% | 14 | $193.23 | |
| 93000 | <1% | 143 | $191.87 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 45,861 | $191.56 |
| 82977 | <1% | 892 | $189.74 | |
| 84436 | <1% | 91 | $184.43 | |
| 83498 | <1% | 13 | $181.65 | |
| 87015 | <1% | 445 | $165.88 | |
| 85018 | <1% | 297 | $163.61 | |
| 81000 | <1% | 2,461 | $161.67 | |
| 83883 | <1% | 14 | $155.76 | |
| 86880 | <1% | 126 | $127.58 | |
| 85014 | <1% | 239 | $126.30 | |
| 36591 | <1% | 15 | $122.96 | |
| 84295 | <1% | 148,385 | $122.31 | |
| 89051 | <1% | 261 | $101.69 | |
| 86580 | <1% | 13 | $100.10 | |
| 95012 | <1% | 205 | $80.14 | |
| 82150 | <1% | 55 | $74.28 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 48,966 | $71.17 |
| 84155 | <1% | 114,362 | $69.61 | |
| 72220 | <1% | 25 | $69.46 | |
| 86036 | <1% | 13 | $69.06 | |
| 84479 | <1% | 35 | $67.98 | |
| 87184 | <1% | 93 | $65.90 | |
| 88142 | <1% | 362 | $57.56 | |
| 93325 | <1% | 2,051 | $56.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 23,956 | $55.71 |
| 87207 | <1% | 106 | $55.02 | |
| 87147 | <1% | 73 | $54.34 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 445 | $50.84 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,758 | $50.64 |
| 93321 | <1% | 214 | $49.20 | |
| 82330 | <1% | 363 | $48.91 | |
| 84300 | <1% | 72 | $46.50 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 29,429 | $43.26 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 11,364 | $42.48 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 315 | $41.46 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 7,498 | $41.35 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 21 | $38.76 |
| 80076 | <1% | 33 | $36.62 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 26 | $33.51 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 7,759 | $32.79 |
| 93226 | <1% | 1,710 | $32.38 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 119 | $30.98 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 660 | $23.30 |
| 85048 | <1% | 14 | $21.78 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 43,691 | $19.24 |
| 82945 | <1% | 588 | $18.75 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,899 | $16.32 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,994 | $15.11 |
| 82948 | <1% | 2,205 | $13.44 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 10,145 | $12.52 |
| 84133 | <1% | 13 | $12.33 | |
| 82375 | <1% | 36 | $11.77 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 403 | $11.45 |
| 87430 | <1% | 626 | $11.45 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,592 | $10.20 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 293 | $9.52 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,729 | $8.65 |
| 85384 | <1% | 43 | $8.11 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 799 | $6.60 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,771 | $6.52 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 760 | $6.24 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 4,629 | $5.49 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 34,358 | $5.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,273 | $4.71 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,595 | $4.48 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | <1% | 40 | $4.40 |
| 85347 | <1% | 110 | $4.07 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,673 | $2.87 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 10,584 | $2.82 |
| J1815 | Injection, insulin, per 5 units | <1% | 6,574 | $2.63 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,639 | $2.25 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 14,496 | $2.14 |
| G0008 | Administration of influenza virus vaccine | <1% | 426 | $2.04 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 263 | $1.84 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 99 | $1.50 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 23,278 | $1.44 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,135 | $1.37 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 6,931 | $1.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 56 | $0.40 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 49 | $0.35 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 45 | $0.31 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 52 | $0.23 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 48 | $0.21 |
| Q9954 | Oral magnetic resonance contrast agent, per 100 ml | 0% | 1,478 | $0.00 |
| 88313 | 0% | 28 | $0.00 | |
| 94729 | 0% | 1,890 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 4,024 | $0.00 |
| 88312 | 0% | 356 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 9,418 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 386 | $0.00 |
| 76376 | 0% | 904 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 627 | $0.00 |
| 93356 | 0% | 1,169 | $0.00 | |
| 64447 | 0% | 25 | $0.00 | |
| C1729 | Catheter, drainage | 0% | 349 | $0.00 |
| 99152 | 0% | 2,701 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 1,959 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 1,777 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 1,224 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 419 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 15,482 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 956 | $0.00 |
| 76827 | 0% | 102 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 727 | $0.00 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 1,216 | $0.00 |
| 76937 | 0% | 361 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 606 | $0.00 |
| 69209 | 0% | 20 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 2,782 | $0.00 |
| T1017 | Case management, billed per 15 minutes | 0% | 79 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 2,132 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 392 | $0.00 |
| 76942 | 0% | 56 | $0.00 | |
| 81401 | 0% | 131 | $0.00 | |
| C1788 | Port, indwelling (implantable) | 0% | 80 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 145 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 324 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 176 | $0.00 |
| 91312 | 0% | 366 | $0.00 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 33 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 135 | $0.00 |
| 80179 | 0% | 24 | $0.00 | |
| 87634 | 0% | 12 | $0.00 | |
| 91300 | 0% | 264 | $0.00 | |
| 92978 | 0% | 15 | $0.00 | |
| 94799 | 0% | 46 | $0.00 | |
| A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | 0% | 122 | $0.00 |
| 96523 | 0% | 14 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 14 | $0.00 |
| 51702 | 0% | 13 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 17 | $0.00 |
| 80143 | 0% | 25 | $0.00 | |
| C1782 | Morcellator | 0% | 33 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 13 | $0.00 |
| C1874 | Stent, coated/covered, with delivery system | 0% | 15 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 16 | $0.00 |
| J3473 | Injection, hyaluronidase, recombinant, 1 usp unit | 0% | 45 | $0.00 |
| 90653 | 0% | 89 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 12 | $0.00 |
| 70320 | 0% | 32 | $0.00 | |
| 93320 | 0% | 1,234 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 1,586 | $0.00 |
| Q4196 | Puraply am, per square centimeter (add-on, list separately in addition to primary procedure) | 0% | 295 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 4,422 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 499 | $0.00 |
| 88341 | 0% | 1,165 | $0.00 | |
| 77001 | 0% | 174 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 882 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,263 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,593 | $0.00 |
| 91305 | 0% | 424 | $0.00 | |
| 64488 | 0% | 55 | $0.00 | |
| 51798 | 0% | 88 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 142 | $0.00 |
| 36416 | 0% | 7,136 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 2,276 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 2,541 | $0.00 |
| S5553 | Insulin, long acting; 5 units | 0% | 538 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 2,380 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 316 | $0.00 |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | 0% | 49 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 13,847 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 1,703 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 904 | $0.00 |
| 80349 | 0% | 68 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 491 | $0.00 |
| C1753 | Catheter, intravascular ultrasound | 0% | 15 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 967 | $0.00 |
| C1769 | Guide wire | 0% | 1,081 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 508 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 2,719 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 425 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 102 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 104 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 422 | $0.00 |
| H2019 | Therapeutic behavioral services, billed per 15 minutes | 0% | 78 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 1,364 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 77 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 65 | $0.00 |
| 80050 | General health panel | 0% | 101 | $0.00 |
| 83930 | 0% | 16 | $0.00 | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | 0% | 15 | $0.00 |
| 90656 | 0% | 57 | $0.00 | |
| 12013 | 0% | 13 | $0.00 | |
| C1819 | Surgical tissue localization and excision device (implantable) | 0% | 138 | $0.00 |
| 74175 | 0% | 13 | $0.00 | |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 41 | $0.00 |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 29 | $0.00 |
| 94660 | 0% | 54 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 103 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 1,074 | $0.00 |
| 91303 | 0% | 66 | $0.00 | |
| 88185 | 0% | 70 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 15 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 44 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWRINN, JACQUELINE (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Yale New Haven Hospital | New Haven, CT | $1.08B |
| Lawrence and Memorial Hospital, INC. | New London, CT | $136.19M |
| Greenwich Hospital | Greenwich, CT | $46.42M |
| Bridgeport Hospital | Milford, CT | $15.60M |
| LMW Healthcare INC. | Westerly, RI | $13.10M |
| Lawrence and Memorial Hospital, INC. | New London, CT | $1.55M |
| Yale New Haven Hospital | New Haven, CT | $629K |
| LMW Healthcare INC. | Westerly, RI | $492K |
| Bridgeport Hospital | Bridgeport, CT | $398K |
| Lawrence and Memorial Hospital, INC. | New London, CT | $365K |
| Shoreline Endoscopy Center, LLC | Guilford, CT | $19K |
| Yale New Haven Hospital | New Haven, CT | $860.83 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.